Dianthus Therapeutics, Inc. will discuss Phase 2 MaGic trial results of claseprubart in generalized Myasthenia Gravis (gMG) on a conference call and webcast on September 8, 2025. Investors can access the call by phone or webcast through the company’s website. Dianthus Therapeutics is focused on developing monoclonal antibodies for severe autoimmune diseases. For more information, visit www.dianthustx.com and follow them on LinkedIn. Contact Jennifer Davis Ruff for further inquiries.

Read more at GlobeNewswire: Dianthus Therapeutics to Host Conference Call and Webcast